Payment overview · 2025
General Payments
$129.36
7 reported records · 6 companies
Healthcare provider profile · identity verified
Charles Frederick Payne, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MECHANICSVILLE, VA · NPI 1902872880
Verified facts
What the public records show
CMS Open Payments records show Charles Frederick Payne, MD received $129.36 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.43 | 28.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.48 | 17.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.09 | 15.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 14.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.36 | 13.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.15 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $110.51 | 6 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 612 | 203 |
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 113 |
| Lisinopril | Lisinopril | 348 | 113 |
| Alprazolam | Alprazolam | 319 | 81 |
| Omeprazole | Omeprazole | 280 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 90 |
| Metformin Hcl | Metformin Hcl | 254 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 84 |
| Losartan Potassium | Losartan Potassium | 234 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 64 |
| Simvastatin | Simvastatin | 204 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 70 |
| Furosemide | Furosemide | 196 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 50 |
| Prednisone | Prednisone | 154 | 112 |
| Glimepiride | Glimepiride | 143 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 143 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 48 |
| Gabapentin | Gabapentin | 135 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 21 |
| Atenolol | Atenolol | 128 | 42 |
| Bumetanide | Bumetanide | 128 | 35 |
| Potassium Chloride | Potassium Chloride | 126 | 33 |
| Lorazepam | Lorazepam | 123 | 28 |
| Sertraline Hcl | Sertraline Hcl | 118 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 40 |
| Trazodone Hcl | Trazodone Hcl | 115 | 34 |
| Tramadol Hcl | Tramadol Hcl | 107 | 36 |
| Metformin Hcl Er | Metformin Hcl | 100 | 34 |
| Allopurinol | Allopurinol | 99 | 31 |
| Famotidine | Famotidine | 98 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 31 |
| Cefuroxime | Cefuroxime Axetil | 95 | 78 |
| Montelukast Sodium | Montelukast Sodium | 95 | 28 |
| Eliquis | Apixaban | 91 | 22 |
| Ozempic | Semaglutide | 83 | 16 |
| Meloxicam | Meloxicam | 79 | 32 |
| Clonazepam | Clonazepam | 78 | 18 |
| Pregabalin | Pregabalin | 78 | 18 |
| Azithromycin | Azithromycin | 74 | 57 |
| Temazepam | Temazepam | 71 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 22 |
| Bupropion Xl | Bupropion Hcl | 63 | 20 |
| Farxiga | Dapagliflozin Propanediol | 62 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 19 |
| Synthroid | Levothyroxine Sodium | 59 | 19 |
| Ezetimibe | Ezetimibe | 58 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 20 |
| Carvedilol | Carvedilol | 54 | 16 |
| Celecoxib | Celecoxib | 53 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 46 |
| Valsartan | Valsartan | 53 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 16 |
| Finasteride | Finasteride | 52 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 15 |
| Benazepril Hcl | Benazepril Hcl | 51 | 15 |
| Cefdinir | Cefdinir | 50 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Spironolactone | Spironolactone | 46 | 15 |
| Xarelto | Rivaroxaban | 45 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 13 |
| Jardiance | Empagliflozin | 42 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | 15 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 13 |
| Warfarin Sodium | Warfarin Sodium | 34 | 13 |
| Diazepam | Diazepam | 33 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 24 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 11 |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 22 |
| Ondansetron Odt | Ondansetron | 27 | 15 |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 14 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Nystatin | Nystatin | 22 | 11 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Cabergoline | Cabergoline | 19 | suppressed |
| Eplerenone | Eplerenone | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Triazolam | Triazolam | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Meclizine Hcl | Meclizine Hcl | 16 | 15 |
| Zaleplon | Zaleplon | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Linzess | Linaclotide | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.36 · 7 records | Amgen Inc. | ABRYSVO, COMIRNATY, EVENITY, JARDIANCE, Ozempic, PREVNAR 20, PROCLAIM, QULIPTA, Rybelsus, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error